Resmed Inc Drc Stock Net Income
| RSMDFDelisted Stock | USD 17.70 0.00 0.00% |
Resmed Inc DRC fundamentals help investors to digest information that contributes to Resmed's financial success or failures. It also enables traders to predict the movement of Resmed Pink Sheet. The fundamental analysis module provides a way to measure Resmed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Resmed pink sheet.
Resmed |
Resmed Inc DRC Company Net Income Analysis
Resmed's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Resmed Net Income | 779.44 M |
Most of Resmed's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Resmed Inc DRC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Resmed Inc DRC reported net income of 779.44 M. This is 128.38% higher than that of the Healthcare sector and significantly higher than that of the Medical Instruments & Supplies industry. The net income for all United States stocks is 36.51% lower than that of the firm.
Resmed Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Resmed's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Resmed could also be used in its relative valuation, which is a method of valuing Resmed by comparing valuation metrics of similar companies.Resmed is currently under evaluation in net income category among its peers.
Resmed Fundamentals
| Return On Equity | 0.24 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 33.08 B | |||
| Shares Outstanding | 1.47 B | |||
| Shares Owned By Institutions | 7.93 % | |||
| Price To Earning | 28.58 X | |||
| Price To Book | 9.54 X | |||
| Price To Sales | 9.04 X | |||
| Revenue | 3.58 B | |||
| Gross Profit | 2.06 B | |||
| EBITDA | 1.18 B | |||
| Net Income | 779.44 M | |||
| Cash And Equivalents | 273.71 M | |||
| Cash Per Share | 0.47 X | |||
| Total Debt | 765.33 M | |||
| Debt To Equity | 0.27 % | |||
| Current Ratio | 2.80 X | |||
| Book Value Per Share | 6.36 X | |||
| Cash Flow From Operations | 351.15 M | |||
| Earnings Per Share | 0.55 X | |||
| Price To Earnings To Growth | 1.76 X | |||
| Target Price | 11.49 | |||
| Number Of Employees | 8.16 K | |||
| Beta | 0.47 | |||
| Market Capitalization | 34.16 B | |||
| Total Asset | 5.1 M | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 5.1 M | |||
| Last Dividend Paid | 1.72 |
About Resmed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Resmed Inc DRC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Resmed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Resmed Inc DRC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Resmed Pink Sheet
If you are still planning to invest in Resmed Inc DRC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Resmed's history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |